FB 704A

Drug Profile

FB 704A

Alternative Names: FB-704A

Latest Information Update: 30 Dec 2015

Price : $50

At a glance

  • Originator Fountain BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Rheumatoid arthritis

Most Recent Events

  • 22 Sep 2015 Fountain Biopharma has patent protection for FB 704A in Taiwan
  • 10 Dec 2014 Preclinical trials in Rheumatoid arthritis and Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top